Skip to main content
Fig. 1 | BMC Urology

Fig. 1

From: The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men

Fig. 1

Changes in subjective symptoms. a shows changes in the Overactive Bladder Symptom Score (OABSS). Combination therapy with α-1 adrenergic receptor blocker and mirabegron for 12 weeks significantly improved the total OABSS, nighttime frequency (Q2), and urgency (Q3). b shows the change in the International Prostate Symptom Score (IPSS). Combination therapy significantly improved the IPSS total score, IPSS-quality of life, and storage symptoms (frequency [Q2], urgency [Q4], nocturia [Q7], and IPSS-storage symptoms [Q2 + Q4 + Q7]). However, combination therapy did not affect voiding symptoms (incomplete emptying [Q1], intermittency [Q3], weak stream [Q5], straining [Q6], and IPSS-voiding symptoms [Q1 + Q3 + Q5 + Q6]). The white columns show the scores at 0 weeks, and the black columns show scores at 12 weeks. SD, standard deviation

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us